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Introduction. Thalidomide has been associated with both venous and arterial thrombotic events. Case Presentation. A 66-years
old man during thalidomide therapy for myeloma experienced acute right arm ischemia, emergently treated with thrombectomy
and, on postoperative day one left side weakness with right internal carotid thrombosis. Discussion. Because of the increased
risk of arterial thrombosis complication, prophylactic therapy with ASA or anticoagulation during thalidomide administration is
mandatory.
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1.Introduction
The antiangiogenic properties of thalidomide have brought
to its use in the treatment of multiple myeloma (MM) and
other neoplastic disease. However, thalidomide has been
associated with venous thrombotic events and, more rarely,
with arterial thrombisis.
We report a case of multiple arterial thrombosis in a MM
patient treated with thalidomide.
2. Case Presentation
A 66-years old man had a one-year history of MM treated
with chemotherapy and stem cell transplantation followed
by a thalidomide plus prednisone regimen (thalidomide
100mg/day and prednisone 12.5mg/day). No prophylactic
antithrombotic therapy was initiated. After two months
of thalidomide plus prednisone therapy, he was admitted
to our hospital with acute right arm ischemia, which
was emergently treated with thrombectomy of the right
brachio-cephalictrunk.Onpostoperativedayonethepatient
experienced left side weakness with right internal carotid
thrombosis documented at duplex scanning and angiogra-
phy study (Figures 1(a) and 1(b)). The CT scan at 48 hours
after neurological symptoms, showed two acute cerebral
infarctions in the frontal lobe with no haemorrhage. No
cardiovascular risk or procoagulant risk factors were found,
and the basic coagulation parameters were normal before
surgery. Other embolic sources were excluded by ECG and
transthoracic echocardiography.
Thalidomide treatment were the only risk factor associ-
ated with arterial thrombosis and therefore was immediately
stopped. Enoxiparine (4000IU twice a day) and acetil-
salicilic acid (ASA-100mg/die), was administrated for ﬁve
days,withsubsequentadministrationofwarfarin(INRrange
2–2.5) and ASA 100mg/day.
With anticoagulation therapy the patient was free of
further signs of new ischemic events.
After discharge was initiated a rehabilitative program,
with complete regression of arm and leg weakness in 1
month.
3. Discussion
Thalidomide is one of the most used drugs in the treatment
of newly diagnosed and relapsed/refractory MM and is cur-
rently used together with cytotoxic chemotherapy because
of its antiangiogenic properties. Continuos low dose of
thalidomide and low dose prednisone was part of main-
tenance program posttransplant [1–3]. The thalidomide’s
antiangiogenic mechanism is thought to involve blocking
(vascular endothelial growth factor) VEGF and ﬁbroblast
growth factor activity, resulting in increased MM cell apop-
tosis [2]. Thalidomide is likely to determine a prothrombotic2 Case Reports in Medicine
Table 1: Arterial complication during Thalidomide administration for MM.
Author N Localization Cytotoxic/corticosteroid therapy TEE∗ prophylaxis
Bowcock 2002 [6] 2 Cerebral None none
Scarpace 2005 [7] 4 Tibial-Cerebral Cytotoxic and corticosteroid VAD◦protocol none
Ortin 2006 [8] 1 Cerebral Cytotoxic and corticosteroid none
Goz 2007 [9] 2 Ilio-femoral-popliteal VAD◦protocol none
Altinas 2007 [10]2 F e m o r a l - T i b i a l V A D ◦protocol and corticosteroid none
∗ TEE (thrombo-embolic events). ◦VAD protocol (vincristine, adriamycine, dexamethasone)
(a) (b)
Figure 1: (a) Angiography of the aortic arch. (b) The angiography
shows internal carotid occlusion.
eﬀect due to a decrease in anticoagulant proteins and an
increase in platelet aggregation and procoagulants proteins;
however this prothrombotic mechanism is not completely
known yet [4]. The prothrombotic eﬀect can be increased
by additional cytotoxic or corticosteroid therapy, due to
endothelial damage or expression of procoagulant factors
[4, 5].
While the increased thrombo-embolic risk of thalido-
mide therapy is widely described in the venous system [6,
11, 12], the arterial complications are scarcely known. A
review of the literature using the keywords “Thalidomide
AND arterial thrombosis AND multiple myeloma—limits:
English” allowed us to ﬁnd out 11 previous cases [6–10],
as shown in Table 1.I nl i t e r a t u r e[ 6–10]i sd e s c r i b e dﬁ v e
cases of cerebral thrombosis associated with stroke; one
case complicated with mortality [8] and six cases of limb
ischemia, one case complicated with major amputation [8].
None of these cases was under anticoagulation or antiplatted
therapy at symptoms onset. All patients experienced an
unique ischemic event in a precise anatomic region, no
recurrent symptoms were found.
Our case is peculiar because of two consecutive arterial
thrombosiseventsintwodiﬀerentanatomicregion.Probably
the association of both thalidomide and corticosteroid
increasesthethromboticriskduetosynergiceﬀectofthetwo
drugs.
The highest risk of thrombotic events with the thalido-
mide use is within the ﬁrst months of induction therapy,
particulary when thalidomide is concomitantly used with
high dose cytotoxic agents. A prophylactic antithrombotic
therapybyantiplateletandanticoagulantdrugsismandatory
in these cases, however no studies are available to conﬁrm
this assumption [13, 14].
4. Conclusion
Thalidomide is one of the most widely used drugs on the
treatment of MM because of its antiangiogenic properties.
Because of the rare but severe arterial complication, this
side eﬀect should be expected when the thalidomide ther-
apy is administered, especially with concomitant cytotoxic
chemotherapy or corticosteriod therapy. Until future studies
on the mechanism of thalidomide are available, prophylactic
therapy with ASA or anticoagulation during thalidomide
administration is mandatory.
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